Biotechnology News and Research

RSS

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

As the number of deaths related to the pandemic H1N1 virus, commonly known as "swine flu," continues to rise, researchers have been scrambling to decipher its inner workings and explain why the incidence is lower than expected in older adults.

17 Nov 2009

DNA banking: A step toward preserving history and improving the health of future generations

This Thanksgiving Day marks the sixth annual National Family History Day, a U.S. Department of Health and Human Services initiative to encourage families to discuss their health history. Holiday gatherings are excellent opportunities for discussing and documenting family disease backgrounds which can save the lives of loved ones through early detection and preventive measures.

17 Nov 2009

Genzyme receives FDA complete response letter for its Lumizyme marketing application

Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.

17 Nov 2009

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

17 Nov 2009

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

17 Nov 2009

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Targeted Genetics Corporation today announced its financial results for the third quarter ended September 30, 2009.

17 Nov 2009

Kane Biotech to raise $500,000 through private placement

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, today announces a non-brokered private placement offering for gross proceeds of up to $500,000 consisting of up to 3,846,154 units ("Units") at a price of $0.13 per Unit.

16 Nov 2009

Dyadic International reports financial results for the third quarter of 2009

Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors’ report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic’s website at www.dyadic.com.

16 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Drug makers hike prices, lobby hard as reform efforts progress

Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect." The increases "will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year."

16 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Windhover Information selects Oncothyreon's PX-866 among top 10 oncology projects for partnering

Oncothyreon Inc. today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Advanced Cell Technology to raise funds through private placements

Advanced Cell Technology, Inc., announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million.

16 Nov 2009

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Yongye International, Inc. a leading manufacturer, developer and distributor of Shengmingsu brand plant and animal nutrient products in the People's Republic of China (PRC), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease.

16 Nov 2009

Biotechnology News and Research

Molecular makeup of current H1N1 flu strain strikingly different from previous H1N1 strains

DNA banking: A step toward preserving history and improving the health of future generations

Genzyme receives FDA complete response letter for its Lumizyme marketing application

Genentech submits sBLAs to the FDA for Avastin

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Scientists find major genetic differences between the pandemic H1N1 strain and seasonal strains

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Kane Biotech to raise $500,000 through private placement

Dyadic International reports financial results for the third quarter of 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Drug makers hike prices, lobby hard as reform efforts progress

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

Windhover Information selects Oncothyreon's PX-866 among top 10 oncology projects for partnering

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Advanced Cell Technology to raise funds through private placements

Yongye International revenues increases 60.9% year-over-year in third quarter 2009

Normal synaptic activity in nerve cells protects brain from Huntington's disease

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News